Navigation Links
Medicines derived from cannabis: a review of adverse events
Date:6/16/2008

This release is available in French.

Montreal, 13 June 2008 Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.

Several drugs containing compounds derived from the cannabis plant, or cannibinoids, are available for medical purposes in Canada. As the use of cannabinoid medications increases, so do concerns about their potential to cause "adverse events," or negative side effects. Dr. Mark Ware, Dr. Stan Shapiro and PhD candidate Tongtong Wang of the Research Institute of the McGill University Health Centre and McGill University, and Dr. Jean-Paul Collet of the University of British Columbia examined the nature of these potential adverse events in a study which will be published June 16 in the Canadian Medical Association Journal (CMAJ).

The study was based on the adverse events reported in 31 separate clinical studies of cannabinoid medications conducted between 1966 and 2007. Adverse events were categorized as either serious or non-serious; with serious adverse events defined as those leading to death, hospitalization or disability.

"Overall, we found an 86% increase in the rate of non-serious adverse events among the patients treated with cannabinoids compared to the patients in the control groups," said Ware, a neurosciences researcher at the Research Institute of the MUHC and assistant professor in anesthesia at McGill's Faculty of Medicine The majority of events were mild to moderate in severity.

The majority of non-serious adverse events observed affected the nervous system, mainly dizziness and drowsiness. "Cannabinoids are used as medicines because they are neurologically active, so we expected to see some side effects such as these," said Wang, a PhD candidate in epidemiology and biostatistics at McGill University.

Cannabinoids have been shown to treat chronic pain resulting from diseases such as cancer, multiple sclerosis, arthritis and fibromyalgia, and also to stimulate appetite and relieve nausea. Physicians must weigh the possible benefits of treatment against the possible side effects in an overall attempt to improve the patient's quality of life.

"We have summarized the adverse events from these studies to help educate physicians and patients about the possible risks of medical cannabinoids," said Collet, formerly at McGill's Department of Epidemiology, and now professor at University of British Columbia, senior researcher at the Child & Family Research Institute and Director of the Centre for Applied Health Research and Evaluation at British Columbia Children's Hospital. "We cannot extend these results to smoked cannabis or recreational use. That will require further research."


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. Human embryonic stem cell -- derived bone tissue closes massive skull injury
2. Curry-derived molecules might be too spicy for colorectal cancers
3. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
4. Human derived stem cells can repair rat hearts damaged by heart attack
5. Stanford researchers publish review of US medical device regulation
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. Faster koa tree growth without adverse ecosystem effects
8. Chemical compound prevents cancer in lab
9. Vobile Launches VideoDNA Live; Enables Real-Time Digital Content Protection for Live Broadcast Events
10. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
11. Device prevents potential errors in childrens medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):
(Date:5/18/2017)... , ... May 18, 2017 , ... ... The Tapas Cooking Challenge is a two-hour team-building package designed for groups ... created by Chef Jodi Abel, which include items, such as Blackened Shrimp with ...
(Date:5/18/2017)... (PRWEB) , ... May 17, 2017 , ... ... specializing in medical device compliance and commercialization, has just released version 9.0 of ... work into this latest version of Cockpit,” says David Cronin, CEO of Cognition. ...
(Date:5/18/2017)... , ... May 17, 2017 , ... ... for example, are more likely to develop Alzheimer’s disease, while men are at ... account for this gender-specific neuronal bias is the aim of a research program ...
(Date:5/16/2017)... ... 16, 2017 , ... Zansors has secured a patent ... or EKG) acquisition and monitoring device. This Zansors’ next-generation intellectual property (IP), will ... the skin, making them significantly easier to deploy and use. , Currently, ECG ...
Breaking Biology Technology: